10 January 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Publication of New Research
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to inform shareholders that a new research note on the Company has recently been published by Pitt Street Research.
The research can be found on the Company's website via the link below:
https://www.roquefortinvest.com/research-reports
ENDS
Enquiries:|
Roquefort Therapeutics plc |
|
|
Stephen West (Chairman) |
+44 (0)20 3290 9339 |
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale Optiva Securities Limited (Broker) |
+44 (0)20 7466 5000 |
|
Christian Dennis |
+44 (0)20 3411 1881 |
For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd ("Lyramid"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.
Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Lyramid's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange�s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.